Basic information about inhibitors

IPAD-DB ID	C00639
Name	Rutin
Category	Natural compounds
2D Structure
3D Structure
Molecular Formula	C 2 7 H 3 0 O 1 6
Molecular Weight	610.5 g/mol
IUPAC Name	2-(3, 4-dihydroxyphenyl)-5, 7-dihydroxy-3-[(2S, 3R, 4S, 5S, 6R)-3, 4, 5-trihydroxy-6-[[(2R, 3R, 4R, 5R, 6S)-3, 4, 5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
InChI	InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6, 8, 15, 17-18, 20-23, 26-33, 35-38H, 7H2, 1H3/t8-, 15+, 17-, 18+, 20+, 21-, 22+, 23+, 26+, 27-/m0/s1
InChIKey	IKGXIBQEEMLURG-NVPNHPEKSA-N
Canonical SMILES	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O
PubChem CID	5280805
DrugBank Accession Number	DB01698
CAS Registry Number	153-18-4, 250249-75-3, 207671-50-9, 1340-08-5

Biological activity data

Ki	-
EC50	-
IC50	-
Inhibition	Reduce 60.8%(APPswe mice Aβ oligomers levels ), reduce 31.7%(PS1dE9 mice Aβ oligomers levels )
Toxicity	-
ROS(reactive oxygen species)	-
Metal Chelating	-
BBB(blood-brain barrier)	-
Target Protein	Aβ oligomers
Effects	(1) Rutin therapy downregulated microgliosis and astrocytosis, increased the activity of superoxide dis-mutase and antioxidant glutathione and its oxidized form ratio, reduced glutathione peroxidase and malondialdehyde levels, as well as decreased interleukin-6 and interleukin-1β levels in the AD mouse brains,
Research Models	APPswe/PS1dE9 mice
Main Source	-
Ref. Link

Physicochemical properties

Molecular Weight(Computed by SwissADME)	610.52
Hac(Computed by SwissADME)	43
Volume(Computed by ADMETlab 2.0)	552.318
Density(Computed by ADMETlab 2.0)	1.105
nRing(Computed by ADMETlab 2.0)	5
MaxRing(Computed by ADMETlab 2.0)	10
nHet(Computed by ADMETlab 2.0)	16
fChar(Computed by ADMETlab 2.0)	0
nRig(Computed by ADMETlab 2.0)	30
Flexibility(Computed by ADMETlab 2.0)	0.2
Stero Centers(Computed by ADMETlab 2.0)	10
LogS(Computed by ADMETlab 2.0)	-3.928
LogD(Computed by ADMETlab 2.0)	0.695

ADMET properties

logP(Computed by ADMETlab 2.0)	-1.69
TPSA(Computed by SwissADME)	269.43 Ų
Hbond Acceptor(Computed by SwissADME)	16
Hbond Donor(Computed by SwissADME)	10
Rotatable Bonds(Computed by SwissADME)	6

Pharmacokinetics

GI Absorption(Computed by SwissADME)	Low
BBB(blood-brain barrier) Permeant(Computed by SwissADME)	No
P-gp Substrate(Computed by SwissADME)	Yes
CYP1A2 Inhibitor(Computed by SwissADME)	No
CYP2C19 Inhibitor(Computed by SwissADME)	No
CYP2C9 Inhibitor(Computed by SwissADME)	No
CYP2D6 Inhibitor(Computed by SwissADME)	No
CYP3A4 Inhibitor(Computed by SwissADME)	No
log Kp(Skin Permeation)(Computed by SwissADME)	-10.26 cm/s

Druglikeness

Lipinski(Computed by SwissADME)	No, 3 violations: MW>500, NorO>10, NHorOH>5
Ghose(Computed by SwissADME)	No, 4 violations: MW>480, WLOGP<-0.4, MR>130, #atoms>70
Veber(Computed by SwissADME)	No, 1 violation: TPSA>140
Egan(Computed by SwissADME)	No, 1 violation: TPSA>131.6
Muegge(Computed by SwissADME)	No, 4 violations: MW>600, TPSA>150, H-acc>10, H-don>5
Bioavailability Score(Computed by SwissADME)	0.17